

---

---

**Aggeliki Lyberopoulou, PhD**

CURRENT POSITION

Biochemist & Molecular Biologist at the Research Laboratory of Internal Medicine, Department of Medicine, University of Thessaly, Greece

**Education/ Training**

INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
Bachelor of Science in Medical Biochemistry, Depart. of Medicine, Univ. of Thessaly	B. Sc.	1999-2002	Medical Biochemistry
Doctorate student at the Laboratory of Biochemistry, Depart. of Medicine, University of Thessaly	PhD	2003-2006	Biochemistry and Molecular Biology

**Personal Info**

Date of Birth: 05 October 1976  
Place of Birth: Athens  
Family Status: Married, One child  
Foreign Languages: English (fluently)  
E-mail: [aglyber@gmail.com](mailto:aglyber@gmail.com), [aliber@uth.gr](mailto:aliber@uth.gr)

ph: +30 2410 685571  
fax: +30 2410 685551

**Experience and Professional Background**

2003-2006: PhD student with funding from the scientific research program PENED 2001/ code 01ED121 entitled: "Molecular mechanisms of cellular response to hypoxia: Activation and function of transcription factor HIF-1".

The title of my doctorate dissertation was "Study of the cellular response to hypoxia: examination of the function of the Hypoxia Inducible Factor 1 $\alpha$  (HIF-1 $\alpha$ )" under the supervision of Ass. Professor Dr. E. Georgatsou. The aim was to identify and investigate new molecular interactions of HIF-1 $\alpha$ . A two-hybrid screen was used and among other proteins that were identified (HAX-1, FLMC etc.), MgcRacGAP, a GTPase Activating Protein, was chosen for further investigation of the structural and biological role of this interaction. This work resulted in two first author publications: Lyberopoulou A et al Cell Physiol Biochem. 2007;20(6):995-1006 and Lyberopoulou A et al Biochim Biophys Acta. 2013 Jun; 1833(6):1378-87

2004: Participation in the laboratory training of post-graduate students of the Dept. of Medicine, Univ. of Thessaly during the course "Cellular signaling and regulation of gene expression" of the Masters Degree program "Clinical applications of molecular medicine".

2005: Participation in the theoretical and practical part of the Workshop on: Modern Methods of "In Light Microscopy and Applications in Biomedical Research and Diagnosis", at the Hellenic Pasteur Institute.

2004-2005: Experimental and scientific supervision of P. Kavvadas, pre-graduate student of the Dept. of Biochemistry and Biotechnology, Univ. of Thessaly, during his diploma thesis entitled: Molecular response to hypoxia: Identification of new molecular interactions of Hypoxia Inducible Factor 1 $\alpha$  (HIF-1 $\alpha$ ), at the Lab. of Biochemistry, Dept. of Medicine.

2007-2009: Biology teacher for high school students that choose to follow higher education in Greek Universities.

2008-2011: Post-doctoral researcher in identifying the biological role of the interaction of the transcription factor HIF-1 $\alpha$  with the MgcRacGAP protein, in the Lab. of Biochemistry, Dept. of Medicine, Univ. of Thessaly.

2008-2009: Experimental and scientific supervision of G. Papachristos, pre-graduate student of the Dept. of Biochemistry and Biotechnology, Univ. of Thessaly, during his diploma thesis entitled: Molecular characterization of the interaction of Hypoxia Inducible Factor 1 $\alpha$  (HIF-1 $\alpha$ ) with MgcRacGAP Myo domain, at the Lab. of Biochemistry, Dept. of Medicine.

2008-2010: Teaching Assistant as a Lecturer for Biochemistry II at the Dept. of Medicine, Univ. of Thessaly during the winter semester of the academic years 2008-2009 και 2009-2010.

2009-2010: Experimental and scientific supervision of E. Karatasiou, pre-graduate student of the Dept. of Biochemistry and Biotechnology, Univ. of Thessaly, during her diploma thesis entitled: Identification of new molecular interactions of HIF-1 $\alpha$  subunit of Hypoxia Inducible Factor 1: HAX-1 protein, at the Lab. of Biochemistry, Dept. of Medicine.

2010-2011: Experimental and scientific supervision of V. Nasikas, MD and MSc student of the Master Course: Clinical Applications of Molecular Medicine, Dept. of Medicine, Univ. of Thessaly, during his thesis entitled: Hypoxia inducible factor-1alpha (HIF-1 $\alpha$ ) polymorphisms and diseases of the musculoskeletal system, at the Lab. of Biochemistry, Dept. of Medicine.

2009-2010: Teaching Assistant as a Lecturer for Biochemistry I at the Dept. of Medicine, Univ. of Thessaly during the summer semester of the academic years 2009 and 2010.

2011-2013: Research in analyzing the production of hepcidin in several liver diseases and identifying its role as a biodiagnostic marker, with convention of entrusting a project, in the scientific research program COOPERATION code 09SYN-12-682 entitled: "Hepcidin Analysis: Automated methods production for hepcidin determination and identification of its diagnostic and pathogenetic role in iron deregulating diseases" in the Lab. of Biochemistry, Dept. of Medicine, Univ. of Thessaly.

2013-2016: Research in next generation sequencing (NGS) analysis of breast and ovarian cancer samples, with convention of entrusting a project, in the scientific research program ARISTEIA I code 1740 entitled: "Extreme Phenotypes in BREast-Ovarian CANcer: Whole exome analysis in very early onset (17-35yrs) cases" in the Lab. of Molecular Oncology, HeCOG, Aristotle University of Thessaloniki and NCSR "Demokritos", Athens.

2014: Technical and scientific guidance to Clinical Oncologists for the evaluation of in situ and molecular markers during round table oral presentation entitled: Targeted massively parallel sequencing or Next Generation Sequencing, 8<sup>th</sup> educational seminar of Molecular Oncology of the Hellenic Institution of Cancer Research.

2015: Technical and scientific guidance to Clinical Oncologists for the evaluation of in situ and molecular markers during round table oral presentation entitled: Data analysis of Next Generation Sequencing that can be parameters for statistical evaluation, 9<sup>th</sup> educational seminar of Molecular Oncology of the Hellenic Institution of Cancer Research.

2016-2017: Research in the sponsored-research program by Gilead sciences Inc. K.A. 70/3/13255: Predictors of sustained off-therapy remission and immunological changes in HBeAg-negative chronic Hepatitis B patients who discontinue effective long-term treatment with nucleos(t)ide analogue(s) in the Lab. of Biochemistry, Dept. of Medicine, Univ. of Thessaly in close collaboration with the Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens.

2016- present: Research and diagnosis of viral and rare autoimmune liver diseases, with convention of entrusting a project in the program code 2466: Study of Chronic Liver Diseases, Research Lab. of Internal Medicine, Depart. of Medicine, Univ. of Thessaly.

## Scholarships

During my doctorate thesis I received a fund from the Hellenic Research Committee, for a period of 20 months (Jan 2004 – Oct 2005).

Bursary for Young Scientists for the participation at the IUBMB/FEBS 2012 Congress in Sevilla, Spain.

## Memberships

IUBMB/ EEBMB

FEBS Constituent Society

## Peer-reviewed publications

1. MgcRacGAP interacts with HIF-1alpha and regulates its transcriptional activity.  
**Lyberopoulou A**, Venieris E, Mylonis I, Chachami G, Pappas I, Simos G, Bonanou S, Georgatsou E. *Cell Physiol Biochem*. 2007;20(6):995-1006.
2. MgcRacGAP, a cytoskeleton regulator, inhibits HIF-1 transcriptional activity by blocking its dimerization.  
**Lyberopoulou A**, Mylonis I, Papachristos G, Sagris D, Kalousi A, Befani C, Liakos P, Simos G, Georgatsou E. *Biochim Biophys Acta*. 2013 Jun;1833(6):1378-87.
3. Oxygen-dependent secretion of a bioactive hepcidin-GFP chimera.  
Chachami G, **Lyberopoulou A**, Kalousi A, Paraskeva E, Pantopoulos K, Simos G. *Biochem Biophys Res Commun*. 2013 Jun 14;435(4):540-5.
4. An association study between hypoxia inducible factor-1alpha (HIF-1α) polymorphisms and osteonecrosis.  
Chachami G, Kalousi A, Papatheodorou L, **Lyberopoulou A**, Nasikas V, Tanimoto K, Simos G, Malizos KN, Georgatsou E. *PLoS One*. 2013 Nov 18;8(11):e79647.
5. Evaluation of two highly-multiplexed custom panels for massively parallel semiconductor sequencing on paraffin DNA.  
Kotoula V, **Lyberopoulou A**, Papadopoulou K, Charalambous E, Alexopoulou Z, Gakou C, Lakis S, Tsolaki E, Lilakos K, Fountzilias G. *PLoS One*. 2015 Jun 3;10(6):e0128818.
6. Low Serum Hepcidin in Patients with Autoimmune Liver Diseases.  
**Lyberopoulou A**, Chachami G, Gatselis NK, Kyratzopoulou E, Saitis A, Gabeta S, Eliades P, Paraskeva E, Zachou K, Koukoulis GK, Mamalaki A, Dalekos GN, Simos G. *PLoS One*. 2015 Aug 13;10(8):e0135486.
7. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.  
Fountzilias G, Giannoulatou E, Alexopoulou Z, Zagouri F, Timotheadou E, Papadopoulou K, Lakis S, Bobos M, Poullos C, Sotiropoulou M, **Lyberopoulou A**, Gogas H, Pentheroudakis G, Pectasides D, Koutras A, Christodoulou C, Papandreou C, Samantas E, Papakostas P, Kosmidis P, Bafaloukos D, Karanikiotis C, Dimopoulos MA, Kotoula V. *Oncotarget*. 2016 May 31;7(22):32731-53.

8. Enhancer of rudimentary homologue interacts with scaffold attachment factor B at the nuclear matrix to regulate SR protein phosphorylation. Drakouli S, **Lyberopoulou A**, Papathanassiou M, Mylonis I, Georgatsou E. *FEBS J*. 2017 Aug;284(15):2482-2500.
9. Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis. Zachou K, Arvaniti P, Azariadis K, Lygoura V, Gatselis NK, **Lyberopoulou A**, Koukoulis GK, Dalekos GN. *Hepatol Res*. 2019 Jan;49(1):96-104.
10. Predictors of HBsAg loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in non-cirrhotic HBeAg-negative chronic hepatitis B. M. Papatheodoridi, E. Hadziyannis, F. Berby, K. Zachou, B. Testoni, E. Rigopoulou, N. K. Gatselis, **A. Lyberopoulou**, I. Vlachogiannakos, S. Manolakopoulos, G. N. Dalekos, F. Zoulim, G. V. Papatheodoridis. *Journal of Viral Hepatitis*, JVH-00210-2019, submitted.
11. Epigenetic modifications in generalized autoimmune epithelitis: Sjögren's Syndrome and Primary Biliary Cholangitis P. Arvaniti, K. Zachou, **A. Lyberopoulou**, N.K. Gatselis, W. H. Brooks, G.D. Dalekos, Y. Renaudineau. *Epigenomes*, accepted 25 July 2019, manuscript ID: epigenomes-530983.

## Announcements

1. **A. Lympelopoulou**, R. Kohen, M. Goudovas, I. Sanidas, G. Panayotou, E. Nikolakaki and E. Georgatsou (2003) Identification and partial characterization of proteins interacting with SAF-B, a nuclear scaffold associated protein. *Hellenic Society of Biochemistry & Molecular Biology, Book of Abstracts, Proceedings of the 55th Meeting*, Vol. 50, pp. 391-396.
2. **A. Lyberopoulou**, G. Gadaras, E. Venieris, S. Bonanou and E. Georgatsou (2004) Detection of new molecular partners of hypoxia inducible factor 1 $\alpha$  (HIF-1 $\alpha$ ). *Hellenic Society of Biochemistry & Molecular Biology, Book of Abstracts of the 56th Meeting*, Vol. 51, p. 85.
3. D. Tsianou, **A. Lyberopoulou**, R. Kohen, S. Bonanou and E. Georgatsou (2005) Analysis of molecules differentially interacting with the highly homologous SAFB1 and SAFB2 proteins. *Hellenic Society of Biochemistry & Molecular Biology, Book of Abstracts, Proceedings of the 57th Meeting*, Vol. 52, p. 210.
4. **A. Lyberopoulou**, G. Gadaras, E. Venieris, G. Chachami, G. Simos, S. Bonanou and E. Georgatsou (2005) Detection of new molecular partners of HIF-1 $\alpha$  (Hypoxia Inducible Factor 1 $\alpha$ ). *1<sup>o</sup> Panhellenic Congress of the Hellenic Society of Basic Medical Sciences, "From the Laboratory Examination to the Clinical Use and Action"*, Proceedings p. 103.
5. **A. Lyberopoulou**, G. Gadaras, E. Venieris, G. Chachami, G. Simos, S. Bonanou and E. Georgatsou (2005) Detection of new molecular partners of hypoxia inducible factor 1 $\alpha$  (HIF-1 $\alpha$ ). *30<sup>th</sup> FEBS Congress & 9<sup>th</sup> IUBMB Conference, The FEBS Journal*, Vol. 272, Supplement 1, Abstracts, 12.
6. **A. Lyberopoulou**, E. Venieris, I. Mylonis, G. Chachami, I. Pappas, G. Simos, S. Bonanou and E. Georgatsou (2007) MgcRacGAP interacts with HIF-1 $\alpha$  and regulates its transcriptional activity. *Hellenic Society of Biochemistry & Molecular Biology, Book of Abstracts, Proceedings of the 59th Meeting*, Vol. 54, p. 179.
7. **A. Lyberopoulou**, G. Papachristos, D. Sagris, A. Kalousi, G. Simos and E. Georgatsou (2009) MgcRacGAP inhibits HIF-1 transcriptional activity by interfering with HIF-1 $\alpha$ -ARNT dimerization. *Hellenic Society of Biochemistry & Molecular Biology, Book of Abstracts, Proceedings of the 60th Meeting*, Vol. 55, p. 117.
8. D. Sagris, E. Georgatsou, **A. Lyberopoulou** (2010) MgcRacGAP inhibits the transcriptional activity of HIF-1 by interfering with the dimerisation of its two subunits. *Scientific Society of Hellenic Medical Students, Book of*

9. **A. Lyberopoulou**, G. Chachami, N. Gatselis, P. Eliades, E. Paraskeva, K. Zachou, A. Mamalaki, G. Dalekos and G. Simos (2012) Determination and significance of serum hepcidin and liver hepcidin mRNA levels in patients with hepatopathies. *22nd IUBMB and 37th FEBS Congress, FEBS Journal, Volume 279, Supplement 1*, p. 102.
10. **A. Lyberopoulou**, I. Mylonis, G. Papachristos, D. Sagris, A. Kalousi, C. Befani, P. Liakos, Simos G. and Georgatsou E (2012) MgcRacGAP, a cytoskeleton regulator, inhibits HIF-1 transcriptional activity in an oxygen-independent manner by blocking its dimerization. *Hellenic Society of Biochemistry & Molecular Biology, Book of Abstracts, Proceedings of the 63th Meeting, Vol. 58*.
11. N.K. Gatselis, K. Zachou, **A. Lyberopoulou**, G. Chachami, S. Saitis, S. Gabeta, P. Eliades, E. Paraskeva, A. Mamalaki, G. Simos, G.N. Dalekos (2013) Down-regulation of hepcidin production in patients with autoimmune liver diseases. *13<sup>th</sup> Panhellenic Liver Congress, 9-12 May 2013, Rhodes Island, Hellenic Association for the Study of the Liver (Best oral presentation prize No. 22, p.15)*.
12. E. Georgatsou, S. Drakouli, M. Papathanassiou, D. Tsianou, **A. Lyberopoulou** (2014) ERH structurally differentiates between the highly homologous SAFB1 and SAFB2 proteins. *FEBS EMBO 2014 Conference Abstract no. 3940, The FEBS Journal, Volume 281, Issue s1, September 2014, p. 642*.
13. Kotoula V, Papadopoulou K, Charalambous E, Zagouri F, Lakis S, **Lyberopoulou A**, Tsolaki E, Pentheroudakis G, Lilakos K, Pectasides D, Fountzilias G (2014) Routinely applicable, highly multiplexed triple negative breast cancer (TNBC) genotyping. *American Association for Cancer Research Annual Meeting 2014, Abstract no. 3579*.
14. Kotoula V, Zagouri F, Timotheadou E, Alexopoulou Z, Wirtz RM, **Lyberopoulou A**, Lakis S, Gogas H, Charalambous E, Pentheroudakis G, Pectasides D, Koutras A, Papakostas P, Christodoulou C, Kosmidis P, Kalogeras KT, Fountzilias G (2014) Investigating the clinical relevance of genomic characteristics in Luminal A and B breast cancer (BC). *European Society for Medical Oncology 2014, Abstract no. 7772*.
15. N. Gatselis, **A. Lyberopoulou**, K. Zachou, G. Chachami, P. Eliades, S. Gabeta, E. Paraskeva, A. Mamalaki, GK. Koukoulis, G. Simos, GN. Dalekos (2014) Down-regulation of hepcidin production in patients with autoimmune liver diseases. *American Association for the Study of Liver Diseases, The Liver Meeting 2014, Abstract no. 329. Hepatology 60, (4)*.
16. Kotoula V, **Lyberopoulou A**, Papadopoulou K, Charalambous E, Lakis S, Alexopoulou Z, Tsolaki E, Lilakos K, Fountzilias G (2015) Evaluation of highly-multiplexed custom panels for targeted massively parallel semiconductor sequencing on paraffin DNA. *American Association for Cancer Research Annual Meeting 2015, Abstract no. 4740*.
17. Fountzilias G, Dimopoulos MA, Kouvatseas G, Timotheadou E, Pentheroudakis GE, Gogas H, Pectasides DG, Christodoulou C, Charalambous E, **Lyberopoulou A**, Linardou H, Papandreou C, Psyrris A, Aravantinos G, Markopoulos C, Venizelos V, Efstratiou I, Kalogeras KT, Lakis S, Kotoula V (2015) Effect of mutant TP53 genotypes on the outcome of breast cancer (BC) patients in different clinical tumor subtypes. *American Society of Clinical Oncology Annual Meeting, Abstract no. 11041, J Clin Oncol 33*.
18. Drakouli S., Papathanassiou M., **Lyberopoulou A.**, Mylonis I., Georgatsou E. (2016) Novel ERH-SAFB1/2 interaction corroborates their role in splicing. *67<sup>o</sup> Panhellenic Conference of the Hellenic Society of Biochemistry and Molecular Biology (HSBMB), Book of Abstracts p.18*.

19. Papatheodoridi M., Hadziyannis E., Rigopoulou E., Zachou K., Xourafas V., **Lyberopoulou A.**, Gatselis N.K., Manolakopoulos S., Dalekos G.N., Papatheodoridis G. (2017) Interferon-Induced Protein-10 (IP10) at Entecavir (ETV) or Tenofovir (TDF) discontinuation in noncirrhotic HBeAg-Negative chronic hepatitis B (CHBe-) cannot predict subsequent relapses. DARING-B: Prospective Greek Study. *9th International Congress of Internal Medicine, 9-11 March 2017, Greece (oral presentation OP10)*.
20. Lygoura V, **Lyberopoulou A.** Exarchou E. Gatselis N., Zachou K., Dalekos G.N. (2017) Increased cholestatic enzymes in patients with a long history of ulcerative colitis: Think for Primary Billiary Cholangitis (PBC) not only for Primary Sclerosing Cholangitidis (PSC). *15th Panhellenic Liver Congress, 25-27 May, Larissa, Greece, Hellenic Association for the Study of the Liver (poster presentation ePP056)*.
21. M. Papatheodoridis, E. Hadziyannis, E. Rigopoulou, K. Zachou, V. Xourafas, **A. Lyberopoulou**, N. Gatselis, A. Georgiou, S. Manolakopoulos, G. Dalekos, G. Papatheodoridis (2017) IP10 significance in HBeAg-negative chronic hepatitis B patients after discontinuation of effective long-term Entecavir or Tenofovir therapy: Results from the DARING-B prospective Greek study. *15th Panhellenic Liver Congress, 25-27 May 2017, Larissa, Greece, Hellenic Association for the Study of the Liver (Best oral presentation prize, EA27)*.
22. M. Papatheodoridis, E. Rigopoulou, E. Hadziyannis, K. Zachou, V. Xourafas, **A. Lyberopoulou**, N. Gatselis, I. Vlachogiannakos, S. Manolakopoulos, G. Dalekos, G. Papatheodoridis (2018) Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in noncirrhotic HBeAg-negative chronic hepatitis B patients: Results from the DARING-B prospective Greek study. *The International Liver Congress 2018, EASL, Journal of Hepatology 2018 (vol. 68, S65–S104, PS-159)*.
23. M. Papatheodoridis, E. Rigopoulou, E. Hadziyannis, K. Zachou, V. Xourafas, **A. Lyberopoulou**, N. Gatselis, S. Manolakopoulos, G. Dalekos, G. Papatheodoridis (2018) Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in noncirrhotic HBeAg-negative chronic hepatitis B patients. *16th Panhellenic Liver Congress, 4-6 May 2018, Athens, Greece, Hellenic Association for the Study of the Liver (oral presentation EA28)*.
24. M. Papatheodoridis, E. Hadziyannis, F. Berby, E. Rigopoulou, K. Zachou, B. Testoni, **A. Lyberopoulou**, N.K. Gatselis, I. Vlachogiannakos, S. Manolakopoulos, G.N. Dalekos, F. Zoulim, G.V. Papatheodoridis (2018) Predictability of serum HBcrAg, HBsAg and Interferon Inducible Protein 10 (IP10) levels in non-cirrhotic Hbeag-Negative chronic Hepatitis B patients who discontinue entecavir (ETV) or Tenofovir (TDF) therapy: Results from the prospective Daring-B study. *American Association for the Study of Liver Diseases, The Liver Meeting 2018, Abstract no. 408. Hepatology 68, (1)*.
25. M. Papatheodoridis, F. Berby, B. Testoni, E. Hadziyannis, K. Zachou, **A. Lyberopoulou**, G.N. Dalekos, F. Zoulim, G.V. Papatheodoridis (2018) Kinetics of serum Hepatitis B core related antigen (HBcrAg) in non-Cirrhotic Hbeag-negative Chronic Hepatitis B (CHBe-) patients who discontinue effective long treatment therapy with entecavir (ETV) or tenofovir disoproxil fumarate (TDF). *American Association for the Study of Liver Diseases, The Liver Meeting 2018, Abstract no. 446. Hepatology 68, (1)*.
26. P. Arvaniti, K. Zachou, **A. Lyberopoulou**, E. Sevdali, M. Speletas, Y. Renaudineau, G. N. Dalekos (2019) Altered expression of DNA methylation/hydroxymethylation enzymes in patients with autoimmune hepatitis (AIH). *18th*

European Congress of Internal Medicine, 29-31 August, Lisbon, Portugal, European Federation of Internal Medicine (EFIM).

---